In this issue:
Impact of the COVID‑19 pandemic on Australians living with MS
MS treatments listed in the WHO EML
CMSC Best Practices: Use of sNfL in MS management
2023 revision of the MENACTRIMS guidelines
Consensus QIs for monitoring MS
Approaches for managing NP in MS
Vitamin D3 supplementation does not reduce MS disease activity
Clinically definite relapsing-remitting MS
Expansion of the CTG PBS Co-Payment Program
Ocrelizumab approved as an injection to treat MS in the UK
Commercialising AI to unlock the mystery of MS
MS Australia’s response to the 2024–25 Federal Budget
The RACP Member Wellbeing Framework is now available
COVID-19 resources
Conferences, workshops, and CPD
Please login below to download this issue (PDF)